Targeting hepatic serine-arginine protein kinase 2 ameliorates alcohol-associated liver disease by alternative splicing control of lipogenesis
Conclusions: These studies reveal that (1) the regulation of alternative splicing by SRPK2 is
implicated in lipogenesis in humans with ALD;(2) FGF21 is a key hepatokine that
ameliorates ALD pathologies largely by inhibiting SRPK2; and (3) targeting SRPK2
signaling by FGF21 may offer potential therapeutic approaches to combat ALD.
implicated in lipogenesis in humans with ALD;(2) FGF21 is a key hepatokine that
ameliorates ALD pathologies largely by inhibiting SRPK2; and (3) targeting SRPK2
signaling by FGF21 may offer potential therapeutic approaches to combat ALD.